Verrica Pharmaceuticals Inc

NASDAQ:VRCA   3:59:44 PM EDT
9.47
-0.13 (-1.35%)
Products

Verrica Pharma Announces Receipt Of Final FDA Minutes Following Type A Meeting Regarding Resubmission Of The NDA For VP-102 In Molluscum

Published: 11/17/2020 12:43 GMT
Verrica Pharmaceuticals Inc. (VRCA) - Verrica Pharmaceuticals Announces Receipt of Final FDA Minutes Following Type a Meeting Regarding Resubmission of the NDA for Vp-102 in Molluscum.
Verrica Pharmaceuticals - Human Factors Study Protocol Has Been Reviewed by FDA and We Are Preparing to Complete That Study by End of Year.
Verrica Pharmaceuticals - Reaffirm Expectation to Resubmit NDA for Vp-102 Pursuant to Statutory 505(b)(1) Regulatory Pathway in Q1 of 2021.
Verrica Pharmaceuticals - Intends to Request an End-of-phase 2 Meeting With FDA for Vp-102 in Egw in Q1 of 2021.